Orbus Therapeutics is a late-stage, private biopharmaceutical company based in Palo Alto focused on developing therapies for rare diseases. Its lead product candidate, eflornithine, is being evaluated in the pivotal STELLAR Phase 3 trial for recurrent anaplastic astrocytoma. The company is planning additional clinical studies of eflornithine in other malignant gliomas. STELLAR began in late 2016, involves more than 85 clinical trial centers across eight countries, and plans to enroll approximately 340 patients with overall survival as the primary endpoint. Eflornithine has received FDA Orphan Drug and Breakthrough Therapy designations and Orphan Medicinal Product status from the CHMP/EMA. The company expanded its Series A financing to support the ongoing STELLAR study and upcoming trials. Orbus Therapeutics is a clinical-stage biopharmaceutical company based in Palo Alto, California, focused on developing and commercializing therapies for rare diseases. Its lead product candidate is eflornithine, described as a novel cytostatic agent, being developed to treat patients with recurrent anaplastic astrocytoma (rAA), a rare central nervous system cancer. The company is led by co‑founder and CEO Bob Myers. Orbus completed a $32.5M Series A financing to advance its clinical work. Management intends to use the proceeds to conduct a Phase 3 clinical trial evaluating eflornithine. Dr. Ernest Mario participated in the financing and joined the company as Chairman of the Board.

Total raised

$104M

Funding rounds

2

Latest round

Series A

Latest activity

Oct 2020